Animal Model Market: How Changing Research Priorities Are Reshaping the Demand for Laboratory Models

The pharmaceutical and biotechnology industries are changing how they approach drug discovery, disease research, and preclinical testing. As researchers work to develop more effective treatments, animal models continue to play an important role in understanding disease mechanisms, evaluating drug responses, and studying the safety of potential therapies.

However, the industry is also going through a transition. Growing interest in human-based research methods, organoids, computational models, and other alternatives is encouraging research organizations to reconsider how and when animal models are used.

Request full Report Pricing and Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-3141

Animal Model Market Size and Growth Forecast

According to Future Market Insights, the global animal model market is estimated to reach USD 2.1 billion in 2026, compared with USD 2.0 billion in 2025. The market is projected to grow to USD 3.8 billion by 2036, registering a CAGR of 6.1% during the 2026–2036 forecast period.

This growth reflects a change in purchasing patterns across the research industry. Although animal use is declining in several major research countries, demand for genetically engineered and humanized models is creating opportunities for higher-value products.

For example, genetically altered animals accounted for 50.0% of scientific animal uses in France in 2024. In Japan, sales of genetically modified mice increased by 5.7% during the year ending March 2025, even as total mouse sales declined.

This indicates that market growth is not necessarily dependent on increasing animal numbers. Instead, specialized models, customized breeding, and additional research services are becoming important sources of value for suppliers.

Four Factors Driving Changes in the Animal Model Market

1. Growing Demand for Genetically Engineered Animal Models

Researchers increasingly require animal models that can replicate specific genetic conditions or disease characteristics. Genetically engineered models help scientists investigate how particular genes influence disease development and treatment responses.

These models are especially useful in oncology, immunology, and rare disease research, where understanding genetic mechanisms is important.

For suppliers, this creates opportunities to offer specialized strains, customized breeding services, and genetic characterization rather than relying entirely on conventional laboratory animals.

2. Rising Use of Animal Models in Drug Discovery and Development

Drug discovery and development are expected to account for 55.0% of the application segment in 2026.

Before new treatments reach clinical trials, pharmaceutical companies need to understand their potential effectiveness, safety, and biological responses. Animal models continue to support several preclinical research activities, particularly where whole-organism studies are required.

Regulated research also creates demand for specific strains, controlled study conditions, and reliable animal supply.

As pharmaceutical pipelines develop, suppliers offering specialized models alongside preclinical research support may find additional commercial opportunities.

3. Increasing Preference for Mice in Research Applications

Mice are projected to account for 65.0% of the animal model market by species in 2026.

Their relatively short breeding cycles, established genetic research tools, and suitability for disease modelling make them widely used across academic and pharmaceutical research.

Genetically modified and humanized mice are particularly valuable because they allow researchers to investigate specific biological pathways and evaluate potential treatments.

As research requirements become more specialized, suppliers capable of maintaining healthy colonies and delivering genetically characterized mouse strains may gain an advantage.

4. Expanding Requirements Across Academic and Research Institutions

Academic and research institutions are expected to hold 38.8% of the end-user segment in 2026.

Universities and public research organizations conduct studies across genetics, neuroscience, immunology, oncology, and other scientific fields. These activities require access to different animal species and specialized research models.

However, purchasing decisions are also influenced by research grants, institutional budgets, and government funding policies.

For suppliers, maintaining strong relationships with research institutions and offering dependable breeding, delivery, and technical support will remain important.

Which Countries Offer the Strongest Growth Opportunities?

Growth opportunities in the animal model industry vary across countries depending on pharmaceutical research activity, government funding, regulatory requirements, and the availability of specialized breeding facilities.

According to Future Market Insights, the projected country-level CAGRs for 2026–2036 are:

·         United States: 7.5%

·         Japan: 6.5%

·         Germany: 6.4%

·         France: 6.3%

·         United Kingdom: 5.9%

The United States is expected to lead growth among the countries covered in the analysis. Although federal research funding is increasingly supporting human-based research methods, pharmaceutical companies continue to require specialized models for preclinical development. Demand for humanized mice and advanced research services could create additional opportunities for suppliers.

Challenges That Animal Model Suppliers Need to Address

Although the market outlook remains positive, animal model suppliers face several challenges that could influence future demand.

One of the most important developments is the growing adoption of non-animal research methods. Organoids, computational models, and other new approach methodologies are receiving increased attention from regulators and research funding organizations.

The US National Institutes of Health has also increased its support for human-based research methods, creating additional pressure on conventional animal testing applications.

Regulatory changes are another important consideration. The FDA's March 2026 draft guidance outlines validation principles for alternative methods, including their relevance to human biology and their intended context of use.

Competitive Landscape of the Animal Model Industry

The animal model industry includes companies specializing in laboratory animal breeding, genetically engineered strains, humanized models, and preclinical research services.

Key companies covered in the Future Market Insights analysis include Charles River Laboratories International, Inc., The Jackson Laboratory, Taconic Biosciences, Inc., genOway S.A., Crown Bioscience, Inotiv, Inc., and GemPharmatech Co., Ltd.

Competition is increasingly influenced by genetic expertise, animal health standards, specialized strain availability, and the ability to support researchers throughout preclinical development.

Companies are also exploring opportunities beyond conventional animal supply. For example, Taconic Biosciences acquired TransCure bioServices in January 2026, strengthening its capabilities in humanized mouse models and preclinical research services.

Similarly, suppliers are exploring organoid, stem cell, and computational research models to respond to changing industry requirements.

As the market develops, companies that combine specialized animal models with technical expertise and complementary non-animal research capabilities may be better positioned to maintain long-term relationships with pharmaceutical and biotechnology customers.

What Lies Ahead for the Animal Model Market?

The future of the animal model market will depend on how research organizations balance traditional laboratory studies with emerging alternatives.

Genetically engineered and humanized models are likely to remain important in areas such as oncology, immunology, and complex disease research. At the same time, regulatory acceptance of non-animal methods could gradually reduce demand for certain conventional testing applications.

For suppliers, this creates a need to rethink their product portfolios. Specialized breeding, customized research models, reliable supply networks, and additional preclinical services could become important competitive advantages.

To understand the market's projected growth, species-wise opportunities, application segments, country-level forecasts, and competitive developments, explore the

https://www.futuremarketinsights.com/reports/animal-model-market

The report provides an in-depth assessment of the global industry from 2026 to 2036, covering animal species, end users, research applications, regional developments, market trends, regulatory changes, and key industry participants.